Nouri-Aria K T, Koskinas J, Tibbs C J, Portmann B C, Williams R
Institute of Liver Studies, King's College School of Medicine and Dentistry, London.
Gut. 1995 Apr;36(4):599-603. doi: 10.1136/gut.36.4.599.
Soluble intercellular adhesion molecule-1 (sICAM-1) is probably released from a variety of cells, including leukocytes and endothelial cells at sites of inflammation or in the circulation, and serum levels may therefore be used to give an indication of immune activation and inflammatory processes. In the present study, an ELISA was used to measure serum ICAM-1 levels in 43 patients with chronic hepatitis C and these were correlated with histological changes in the liver and the response to interferon alpha treatment. Serum ICAM-1 levels were significantly higher in patients with chronic hepatitis C infection than in normal subjects and correlated positively with the grade of histological activity, in particular the degree of portal, periportal, and lobular inflammation, but not with the presence of lymphoid aggregates. There was also a weak but significant positive correlation between sICAM-1 and serum aspartate aminotransferase activities, and sICAM-1 levels were substantially greater in patients with than those without cirrhosis. Serum ICAM-1 levels fell significantly in 11 responders out of 19 patients treated with interferon alpha, whereas levels remained unchanged in the non-responder group. sICAM-1 levels correlate with the clinical status of patients with chronic hepatitis C infection and fall with successful interferon treatment.
可溶性细胞间黏附分子-1（sICAM-1）可能由多种细胞释放，包括炎症部位或循环中的白细胞和内皮细胞，因此血清水平可用于指示免疫激活和炎症过程。在本研究中，采用酶联免疫吸附测定（ELISA）法检测了43例慢性丙型肝炎患者的血清ICAM-1水平，并将其与肝脏组织学变化及α干扰素治疗反应进行关联分析。慢性丙型肝炎感染患者的血清ICAM-1水平显著高于正常受试者，且与组织学活动度分级呈正相关，特别是门静脉、门静脉周围和小叶炎症程度，但与淋巴样聚集物的存在无关。sICAM-1与血清天冬氨酸氨基转移酶活性之间也存在微弱但显著的正相关，肝硬化患者的sICAM-1水平明显高于无肝硬化患者。19例接受α干扰素治疗的患者中有11例反应者的血清ICAM-1水平显著下降，而无反应组患者的水平保持不变。sICAM-1水平与慢性丙型肝炎感染患者的临床状态相关，并随着干扰素治疗成功而下降。
